Nil Patil, Khushalika Patil, Mukul Jain, Arifullah Mohammed, Alpa Yadav, Parmdeep Singh Dhanda, Chittaranjan Kole, Kirtan Dave, Prashant Kaushik, Mohammad Khairul Azhar Abdul Razab, Zulhazman Hamzah, Norazlina Mat Nawi
{"title":"A systematic study of molecular targets of cannabidiol in Alzheimer's disease.","authors":"Nil Patil, Khushalika Patil, Mukul Jain, Arifullah Mohammed, Alpa Yadav, Parmdeep Singh Dhanda, Chittaranjan Kole, Kirtan Dave, Prashant Kaushik, Mohammad Khairul Azhar Abdul Razab, Zulhazman Hamzah, Norazlina Mat Nawi","doi":"10.1177/25424823241284464","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's disease (AD) is a prevalent, incurable, and chronic neurodegenerative condition characterized by the accumulation of amyloid-β protein (Aβ), disrupting various bodily systems. Despite the lack of a cure, phenolic compounds like cannabidiol (CBD), a non-psychoactive component of cannabis, have emerged as potential therapeutic agents for AD.</p><p><strong>Objective: </strong>This systematic review explores the impact of different types of cannabidiol on AD, unveiling their neuroprotective mechanisms.</p><p><strong>Methods: </strong>The research used PubMed, Scopus, and Web of Science databases with keywords like \"Alzheimer's disease\" and \"Cannabidiol.\" Studies were evaluated based on title, abstract, and relevance to treating AD with CBD. No restrictions on research type or publication year. Excluded were hypothesis papers, reviews, books, unavailable articles, etc.</p><p><strong>Results: </strong>Microsoft Excel identified 551 articles, with 92 included in the study, but only 22 were thoroughly evaluated. In-vivo and in-silico studies indicate that CBD may disrupt Aβ<sub>42</sub>, reduce pro-inflammatory molecule release, prevent reactive oxygen species formation, inhibit lipid oxidation, and counteract Aβ-induced increases in intracellular calcium, thereby protecting neurons from apoptosis.</p><p><strong>Conclusions: </strong>In summary, the study indicates that CBD and its analogs reduce the production of Aβ<sub>42</sub>. Overall, these findings support the potential of CBD in alleviating the underlying pathology and symptoms associated with AD, underscoring the crucial need for further rigorous scientific investigation to elucidate the therapeutic applications and mechanisms of CBD in AD.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"8 1","pages":"1339-1360"},"PeriodicalIF":2.8000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863746/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Alzheimer's disease reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25424823241284464","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Alzheimer's disease (AD) is a prevalent, incurable, and chronic neurodegenerative condition characterized by the accumulation of amyloid-β protein (Aβ), disrupting various bodily systems. Despite the lack of a cure, phenolic compounds like cannabidiol (CBD), a non-psychoactive component of cannabis, have emerged as potential therapeutic agents for AD.
Objective: This systematic review explores the impact of different types of cannabidiol on AD, unveiling their neuroprotective mechanisms.
Methods: The research used PubMed, Scopus, and Web of Science databases with keywords like "Alzheimer's disease" and "Cannabidiol." Studies were evaluated based on title, abstract, and relevance to treating AD with CBD. No restrictions on research type or publication year. Excluded were hypothesis papers, reviews, books, unavailable articles, etc.
Results: Microsoft Excel identified 551 articles, with 92 included in the study, but only 22 were thoroughly evaluated. In-vivo and in-silico studies indicate that CBD may disrupt Aβ42, reduce pro-inflammatory molecule release, prevent reactive oxygen species formation, inhibit lipid oxidation, and counteract Aβ-induced increases in intracellular calcium, thereby protecting neurons from apoptosis.
Conclusions: In summary, the study indicates that CBD and its analogs reduce the production of Aβ42. Overall, these findings support the potential of CBD in alleviating the underlying pathology and symptoms associated with AD, underscoring the crucial need for further rigorous scientific investigation to elucidate the therapeutic applications and mechanisms of CBD in AD.
背景:阿尔茨海默病(AD)是一种普遍的、无法治愈的慢性神经退行性疾病,其特征是淀粉样蛋白-β (a β)的积累,破坏各种身体系统。尽管缺乏治愈方法,但大麻二酚(CBD)等酚类化合物(大麻的一种非精神活性成分)已成为阿尔茨海默病的潜在治疗药物。目的:探讨不同类型大麻二酚对AD的影响,揭示其神经保护机制。方法:研究使用PubMed、Scopus和Web of Science数据库,关键词为“阿尔茨海默病”和“大麻二酚”。研究根据标题、摘要和CBD治疗AD的相关性进行评估。对研究类型和发表年份没有限制。排除了假设论文、综述、书籍、不可用文章等。结果:Microsoft Excel识别了551篇文章,其中92篇纳入研究,但只有22篇被彻底评估。体内和计算机研究表明,CBD可能破坏Aβ42,减少促炎分子的释放,阻止活性氧的形成,抑制脂质氧化,并抵消a β诱导的细胞内钙的增加,从而保护神经元免于凋亡。结论:综上所述,本研究表明CBD及其类似物可降低Aβ42的产生。总的来说,这些发现支持CBD在缓解AD相关的潜在病理和症状方面的潜力,强调了进一步严格的科学研究以阐明CBD在AD中的治疗应用和机制的必要性。